FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2193532890> ?p ?o ?g. }

• W2193532890 endingPage "34013" @default.
• W2193532890 startingPage "34004" @default.
• W2193532890 abstract "// Hideo Baba 1,* , Yoshifumi Baba 1,* , Shinji Uemoto 2 , Kazuhiro Yoshida 3 , Akio Saiura 4 , Masayuki Watanabe 4 , Yoshihiko Maehara 5 , Eiji Oki 5 , Yasuharu Ikeda 6 , Hiroyuki Matsuda 7 , Masakazu Yamamoto 8 , Mitsuo Shimada 9 , Akinobu Taketomi 10 , Michiaki Unno 11 , Kenichi Sugihara 12 , Yutaka Ogata 13 , Susumu Eguchi 14 , Seigo Kitano 15 , Kazuo Shirouzu 16 , Yasumitsu Saiki 17 , Hiroshi Takamori 18 , Masaki Mori 19 , Toshihiko Hirata 20 , Go Wakabayashi 21 and Norihiro Kokudo 22 1 Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan 2 Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan 3 Department of Surgical Oncology, Gifu Graduate School of Medicine, Gifu, Japan 4 Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan 5 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan 6 Department of Gastroenterological Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan 7 Department of Surgery, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan 8 Department of Surgery, Tokyo Women’s Medical University, Tokyo, Japan 9 Department of Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan 10 Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan 11 Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan 12 Department of Surgical Oncology, Tokyo Medical and Dental University, Tokyo, Japan 13 Department of Surgery, Kurume University Medical Center, Kurume, Japan 14 Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan 15 Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita, Japan 16 Department of Surgery, Kurume University School of Medicine, Kurume, Japan 17 Coloproctology Center, Takano Hospital, Kumamoto, Japan 18 Department of Surgery, Saiseikai Kumamoto Hospital, Kumamoto, Japan 19 Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan 20 Department of Surgery, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan 21 Department of Surgery, Iwate Medical University, School of Medicine, Morioka, Japan 22 Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan * These authors have contributed equally to this work Correspondence to: Hideo Baba, email: // Keywords : ERCC1, DPYD, VEGFA, colorectal cancer, bevacizumab Received : July 18, 2015 Accepted : August 12, 2015 Published : August 19, 2015 Abstract Our previous study showed that administering oxaliplatin as first-line chemotherapy increased ERCC1 and DPD levels in liver colorectal cancers (CRCs) metastases. Second, whether the anti-VEGF monoclonal antibody bevacizumab alters tumoral VEGFA levels is unknown. We conducted this multicenter observational study to validate our previous findings on ERCC1 and DPD, and clarify the response of VEGFA expression to bavacizumab administration. 346 CRC patients with liver metastases were enrolled at 22 Japanese institutes. Resected liver metastases were available for 175 patients previously treated with oxaliplatin-based chemotherapy (chemotherapy group) and 171 receiving no previous chemotherapy (non-chemotherapy group). ERCC1 , DPYD , and VEGFA mRNA levels were measured by real-time RT-PCR. ERCC1 mRNA expression was significantly higher in the chemotherapy group than in the non-chemotherapy group ( P = 0.033), and were significantly correlated (Spearman’s correlation coefficient = 0.42; P < 0.0001). VEGFA expression level was higher in patients receiving bevacizumab ( n = 51) than in those who did not ( n = 251) ( P = 0.007). This study confirmed that first-line oxaliplatin-based chemotherapy increases ERCC1 and DPYD expression levels, potentially enhancing chemosensitivity to subsequent therapy. We also found that bevacizumab induces VEGFA expression in tumor cells, suggesting a biologic rationale for extending bevacizumab treatment beyond first progression." @default.
• W2193532890 created "2016-06-24" @default.
• W2193532890 creator A5001076934 @default.
• W2193532890 creator A5004420462 @default.
• W2193532890 creator A5011375145 @default.
• W2193532890 creator A5018138745 @default.
• W2193532890 creator A5019575585 @default.
• W2193532890 creator A5021979476 @default.
• W2193532890 creator A5028862176 @default.
• W2193532890 creator A5032856038 @default.
• W2193532890 creator A5033294815 @default.
• W2193532890 creator A5035399792 @default.
• W2193532890 creator A5045334877 @default.
• W2193532890 creator A5049313696 @default.
• W2193532890 creator A5062022557 @default.
• W2193532890 creator A5063723368 @default.
• W2193532890 creator A5066565101 @default.
• W2193532890 creator A5067647817 @default.
• W2193532890 creator A5069774184 @default.
• W2193532890 creator A5072168969 @default.
• W2193532890 creator A5075220614 @default.
• W2193532890 creator A5075811653 @default.
• W2193532890 creator A5078312870 @default.
• W2193532890 creator A5081174788 @default.
• W2193532890 creator A5086139902 @default.
• W2193532890 creator A5086522106 @default.
• W2193532890 creator A5088420388 @default.
• W2193532890 date "2015-08-19" @default.
• W2193532890 modified "2023-10-02" @default.
• W2193532890 title "Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study" @default.
• W2193532890 cites W1967628954 @default.
• W2193532890 cites W1977887541 @default.
• W2193532890 cites W1986195579 @default.
• W2193532890 cites W1989921759 @default.
• W2193532890 cites W2002381738 @default.
• W2193532890 cites W2003232455 @default.
• W2193532890 cites W2006202974 @default.
• W2193532890 cites W2021882503 @default.
• W2193532890 cites W2026084555 @default.
• W2193532890 cites W2043205355 @default.
• W2193532890 cites W2054616520 @default.
• W2193532890 cites W2081238655 @default.
• W2193532890 cites W2101711321 @default.
• W2193532890 cites W2104580737 @default.
• W2193532890 cites W2107277218 @default.
• W2193532890 cites W2111391096 @default.
• W2193532890 cites W2119534563 @default.
• W2193532890 cites W2122298066 @default.
• W2193532890 cites W2123965006 @default.
• W2193532890 cites W2137208309 @default.
• W2193532890 cites W2138983527 @default.
• W2193532890 cites W2141434947 @default.
• W2193532890 cites W2141592427 @default.
• W2193532890 cites W2142167347 @default.
• W2193532890 cites W2147834058 @default.
• W2193532890 cites W2154188825 @default.
• W2193532890 cites W2160373161 @default.
• W2193532890 cites W2164578725 @default.
• W2193532890 cites W2166573361 @default.
• W2193532890 cites W2192080449 @default.
• W2193532890 doi "https://doi.org/10.18632/oncotarget.5227" @default.
• W2193532890 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4741821" @default.
• W2193532890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26372896" @default.
• W2193532890 hasPublicationYear "2015" @default.
• W2193532890 type Work @default.
• W2193532890 sameAs 2193532890 @default.
• W2193532890 citedByCount "13" @default.
• W2193532890 countsByYear W21935328902017 @default.
• W2193532890 countsByYear W21935328902018 @default.
• W2193532890 countsByYear W21935328902020 @default.
• W2193532890 countsByYear W21935328902021 @default.
• W2193532890 crossrefType "journal-article" @default.
• W2193532890 hasAuthorship W2193532890A5001076934 @default.
• W2193532890 hasAuthorship W2193532890A5004420462 @default.
• W2193532890 hasAuthorship W2193532890A5011375145 @default.
• W2193532890 hasAuthorship W2193532890A5018138745 @default.
• W2193532890 hasAuthorship W2193532890A5019575585 @default.
• W2193532890 hasAuthorship W2193532890A5021979476 @default.
• W2193532890 hasAuthorship W2193532890A5028862176 @default.
• W2193532890 hasAuthorship W2193532890A5032856038 @default.
• W2193532890 hasAuthorship W2193532890A5033294815 @default.
• W2193532890 hasAuthorship W2193532890A5035399792 @default.
• W2193532890 hasAuthorship W2193532890A5045334877 @default.
• W2193532890 hasAuthorship W2193532890A5049313696 @default.
• W2193532890 hasAuthorship W2193532890A5062022557 @default.
• W2193532890 hasAuthorship W2193532890A5063723368 @default.
• W2193532890 hasAuthorship W2193532890A5066565101 @default.
• W2193532890 hasAuthorship W2193532890A5067647817 @default.
• W2193532890 hasAuthorship W2193532890A5069774184 @default.
• W2193532890 hasAuthorship W2193532890A5072168969 @default.
• W2193532890 hasAuthorship W2193532890A5075220614 @default.
• W2193532890 hasAuthorship W2193532890A5075811653 @default.
• W2193532890 hasAuthorship W2193532890A5078312870 @default.
• W2193532890 hasAuthorship W2193532890A5081174788 @default.
• W2193532890 hasAuthorship W2193532890A5086139902 @default.
• W2193532890 hasAuthorship W2193532890A5086522106 @default.
• W2193532890 hasAuthorship W2193532890A5088420388 @default.
• W2193532890 hasBestOaLocation W21935328901 @default.

• next